照片-BQCA:积极的体调节器使M1受体的光学控制成为可能
Hubert Gerwe1, Eva Schaller1, Rosalba Sortino2,3,4
1Pharmaceutical and Medicinal Chemistry Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg (JMU), Am Hubland, 97074, Würzburg, Germany.
Angewandte Chemie (International ed. in English)
|August 13, 2024
概括
研究人员为A类G蛋白合受体 (GPCRs) 开发了新的可光开关的全调节器,专门针对M1肌酸乙胆受体. 这些光控制分子为研究GPCR信号提供了新的途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- G蛋白结合受体 (GPCRs) 是关键的药物标,A类代表了最大的家族.
- 可光切换的配体提供了对受体活性的精确时空控制.
- 现有的A类GPCR的可光切换配体主要准正结位.
研究的目的:
- 为A类GPCRs开发第一个可光开关的全调节器.
- 用新型光药学工具研究M1肌酸乙胆受体.
- 为了证明A类GPCRs中光控制的全调制的可行性.
主要方法:
- 设计和合成本基诺碳酸酸 (BQCA) 衍生物.
- 新型化合物的光药理学性质的表征.
- 对M1肌糖乙胆受体活性的全调节的评估.
主要成果:
- 开发Photo-BQCisA和Photo-BQCtrAns,这是A类GPCR的第一个可光切换的基调节器.
- 证明可逆光控制的互补光药理学行为.
- 成功准了M1肌肉酸乙胆受体.
结论:
- 新型BQCA衍生物作为研究M1受体信号的有价值的工具.
- 这项工作在A类GPCR中建立了可光切换的全调节器的概念验证.
- 可光切换的质调制为GPCR研究和药物发现开辟了新的途径.
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Allosteric Regulation
57.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.8K
Cholinergic Receptors: Muscarinic
2.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.1K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
914
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
914
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K


